- Oral
- Parenteral
- Others
Endometriosis is a condition in which the inner ling of uterus develops outside of uterus. Endometriosis is often painful and most commonly involves fallopian tubes, ovaries,and tissue that lining the pelvis. But, rarely endometriosis spreadsbeyond the pelvic organs. Exact cause of endometriosis is not known. Possible causes may be retrograde menstruation, embryonic cell transformation, surgical scar implantation, transformation of peritoneal cells or may be immune system disorders.
Endometriosis generally diagnosed by pelvic exam, ultrasound or through laparoscopy. Endometriosis treated with medications or surgery. Generally medications are preferred over surgical procedure. Medications include NSAIDs to manage pain, and hormones.
Key Developments:
- In November 2017, Abbive Inc. announced detailed results from two replicate phase 3 clinical studies evaluating the long-termefficiency and safety of elagolix, orally administered gonadotrophin-releasinghormone being evaluated for endometriosis associated with pain. The results found to be positive and the results, and other additional abstracts, were presented at the American Society for Reproductive Medicine Scientific Congress & Expo (ASRM) in San Antonio,
- In November 2017, ObsEva SA announcedcompletion of patient recruitment of Phase 2b EDELWEISS clinical trial of itaGnRHreceptor antagonist, OBE2109 for the treatment of pain associated with endometriosis.
Endometriosis Disease Pipeline Drugs Assessment Dynamics
Endometriosis Disease Pipeline Drugs Assessment report studies the various therapeutics under clinical development for Endometriosis treatment along with targets for various drug candidate. The report provides plethora of information pertaining to trail phases, companies involved in the Endometriosis disease pipeline drugs development. This report studies the dynamics of the Endometriosis Disease Pipeline Drugs i.e. drivers, challenges,and opportunities which are significantly impacting the product development. The report provides various information pertaining the clinical trials such as designation, grants, patents, and technology among others. Moreover, the report on Endometriosis disease pipeline drugs assessment comprehensively presents the geographic location, trial status information along with key players involved in the therapeutics development.
Endometriosis Disease Pipeline Drugs Assessment Segmentation
By Route of Administration
By Trial Phase
- Preclinical Trials
- Phase 1
- Phase 2
- Phase 3
Frequently Asked Questions
2023 is the base year and 2030 is the forecast year.
The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).
In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.
Key Features of the Reports
- The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
- The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
- The report tracks recent innovations, key developments, and start-up details that are actively working in the market
- The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
| 1. Executive Summary |
| 2.Global Endometriosis Disease Pipeline Drugs Assessment Market Introduction |
| 2.1.Global Endometriosis Disease Pipeline Drugs Assessment Market - Taxonomy |
| 2.2.Global Endometriosis Disease Pipeline Drugs Assessment Market - Definitions |
| 2.2.1.Route of Administration |
| 2.2.2.Trial Phase |
| 3.Global Endometriosis Disease Pipeline Drugs Assessment Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Product Landscape |
| 3.6. New Product Launches |
| 3.7. Impact of COVID 19 on Market |
| 4.Global Endometriosis Disease Pipeline Drugs Assessment Market Analysis, 2019 - 2023 and Forecast 2024 - 2030 |
| 4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5.Global Endometriosis Disease Pipeline Drugs Assessment Market By Route of Administration, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 5.1. Oral |
| 5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. Parenteral |
| 5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 5.3. Others |
| 5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.3. Market Opportunity Analysis |
| 6. Global Endometriosis Disease Pipeline Drugs Assessment Market By Trial Phase, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 6.1. Preclinical Trials |
| 6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Phase 1 |
| 6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 6.3. Phase 2 |
| 6.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.3.3. Market Opportunity Analysis |
| 6.4. Phase 3 |
| 6.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.4.3. Market Opportunity Analysis |
| 7. Competition Landscape |
| 7.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
| 7.2.1.AbbVie Inc. (U.S.) |
| 7.2.2.ObsEva (Switzerland) |
| 7.2.3.Bayer AG (Germany) |
| 7.2.4.Repros Therapeutics Inc. (U.S.) |
| 8. Research Methodology |
| 9. Appendix and Abbreviations |
- AbbVie Inc. (U.S.)
- ObsEva (Switzerland)
- Bayer AG (Germany)
- Repros Therapeutics Inc. (U.S.)